It’s finally happening! After more than 50 years, the DEA announced in May of last year that it would finally expand access to cannabis for research purposes…thereby ending the more than 50 year monopoly held by the University of Mississippi. This, after decades worth of cited concerns over the poor quality and scarcity of available product to use in research.
This is exciting news for researchers and advocates. Now two more companies have been licensed to grow and harvest modern-day, research-grade cannabis. This is a significant step forward and could create an unprecedented opportunity for research and development of new federally approved therapeutic cannabis-derived medications.
Despite these recent advances, there are still hurdles. The DEA may soon be forced to re-evaluate the scheduling of cannabis under the Controlled Substances Act as more research points to the error in it’s Schedule1 classification.
Read more by clicking the links below: